Cellular immunotherapy for acute myeloid leukemia: How specific should it be?
Jong Bok Lee(University Health Network), Zhang Li(University of Toronto), Daniel Vasić(University Health Network), Arjun Law(University of Toronto), Branson Chen(University Health Network)
Cited by 26
Related Papers
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
|Oncotarget|2017|187
Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
|Blood|2021|145
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies
|Biology of Blood and Marrow Transplantation|2018|92
Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD
|Bone Marrow Transplantation|2020|59
Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats
|Journal of Clinical Medicine|2019|58